Ligand Pharma (LGND) Tops Q3 EPS by 54c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $312.01 -1.29%
Revenue Growth %: +32.4%
Financial Fact:
Total other income (expense), net: -4.26M
Today's EPS Names:
CRMT, FOMI, FLES, More
Revenue Growth %: +32.4%
Financial Fact:
Total other income (expense), net: -4.26M
Today's EPS Names:
CRMT, FOMI, FLES, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.58, $0.54 better than the analyst estimate of $1.04. Revenue for the quarter came in at $64.8 million versus the consensus estimate of $55.65 million.
GUIDANCE:
Ligand Pharma sees FY2021 EPS of $5.80-$6.05, versus the consensus of $5.93. Ligand Pharma sees FY2021 revenue of $265-275 million, versus the consensus of $270 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
- Trump discloses over $1.4 billion in crypto income in 2025 filing
- Culp, Inc. (CULP) Misses Q4 EPS by 12c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
